EPISODE · Aug 22, 2019 · 10 MIN
CytoDyn Joins The Stock Day Podcast to Discuss Phase 3 Trials for Their HIV Program
from Stock Day Media · host Stock Day Media
The Stock Day Podcast welcomed CytoDyn (CYDY)(“the Company”), a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. President and CEO, Dr. Nader Pourhassan, joined Stock Day host Everett Jolly. Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
What this episode covers
The Stock Day Podcast welcomed CytoDyn (CYDY)(“the Company”), a biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. President and CEO, Dr. Nader Pourhassan, joined Stock Day host Everett Jolly. Advertising Inquiries: https://redcircle.com/brands Privacy & Opt-Out: https://redcircle.com/privacy
NOW PLAYING
CytoDyn Joins The Stock Day Podcast to Discuss Phase 3 Trials for Their HIV Program
No transcript for this episode yet
Similar Episodes
Sep 22, 2023 ·20m
Sep 22, 2023 ·20m
Sep 22, 2023 ·27m
Sep 22, 2023 ·14m
Sep 22, 2023 ·24m
Sep 22, 2023 ·22m